The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia

Biomaterials

Volumn 34, Issue 28, 2013, Pages 6893-6905

  Liu, Xin ^a   Ye, Ming ^b   An, Chiying ^c   Pan, Liqiang ^a   Ji, Litong ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cationic bovine serum albumin conjugated PEGylated nanoparticles; Cerebral ischemia; MAPK signal pathways; Neuroprotection; Tanshinone IIA

Indexed keywords

CEREBRAL ISCHEMIA; NEUROPROTECTION; PEGYLATED NANOPARTICLE; SIGNAL PATHWAYS; TANSHINONE II A;

CELL DEATH; CONTROLLED DRUG DELIVERY; MAMMALS;

NEURONS;

BOVINE SERUM ALBUMIN; CATION; CYCLOOXYGENASE 2; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 10; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NANOPARTICLE; STRESS ACTIVATED PROTEIN KINASE; TANSHINONE IIA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DYSFUNCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN NERVE CELL; BRAIN PROTECTION; CIRCULATION TIME; CONJUGATION; CONTROLLED STUDY; DOWN REGULATION; DRUG HALF LIFE; EMULSION; EVAPORATION; FLUORESCENCE ANALYSIS; MALE; NEUROMODULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RING OPENING METATHESIS POLYMERIZATION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; UPREGULATION; WESTERN BLOTTING; ZETA POTENTIAL;

ANIMALS; BRAIN ISCHEMIA; CATTLE; DITERPENES, ABIETANE; MALE; NANOPARTICLES; NEUROPROTECTIVE AGENTS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION;

BOVINAE; RATTUS;

EID: 84879459913     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.021     Document Type: Article

References (58)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
2. Bernardi A., Frozza R.L., Horn A.P., Campos M.M., Calixto J.B., Salbego C., et al. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem Int 2010, 57:629-636.
3. Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007, 54:34-66.
4. Nakka V.P., Gusain A., Mehta S.L., Raghubir R. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol 2008, 37:7-38.
5. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744.
6. Lee K.Y., Bae O.N., Serfozo K., Hejabian S., Moussa A., Reeves M., et al. Asiatic acid attenuates infarct volume, mitochondrial dysfunction, and matrix metalloproteinase-9 induction after focal cerebral ischemia. Stroke 2012, 43:1632-1638.
7. Wang L.C., Huang C.Y., Wang H.K., Wu M.H., Tsai K.J. Magnesium sulfate and nimesulide have synergistic effects on rescuing brain damage after transient focal ischemia. JNeurotraum 2012, 29:1518-1529.
8. Khan M.M., Gandhi C., Chauhan N., Stevens J.W., Motto D.G., Lentz S.R., et al. Alternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice. Stroke 2012, 43:1376-1382.
9. Vila N., Castillo J., Dávalos A., Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325-2329.
10. Lin Z., Zhu D., Yan Y., Yu B. Herbal formula FBD extracts prevented brain injury and inflammation induced by cerebral ischemia-reperfusion. JEthnopharmacol 2008, 118:140-147.
11. Frenkel D., Huang Z., Maron R., Koldzic D.N., Hancock W.W., Moskowitz M.A., et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10 producing CD4+ T cells. JImmunol 2003, 171:6549-6555.
12. Ooboshi H., Ibayashi S., Shichita T., Kumai Y., Takada J., Ago T., et al. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 2005, 111:913-919.
13. Ren X., Akiyoshi K., Dziennis S., Vandenbark A.A., Herson P.S., Hurn P.D., et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. JNeurosci 2011, 31:8556-8563.
14. Welser J.V., Li L., Milner R. Microglial activation state exerts a biphasic influence on brain endothelial cell proliferation by regulating the balance of TNF and TGF-β1. JNeuroinflammation 2010, 89:1-7.
15. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Stroke 1998, 29:1020-1030.
16. Planas A.M., Sole S., Justica C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001, 8:834-846.
17. Svedin P., Hagberg H., Savman K., Zhu C., Mallard C. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. JNeurosci 2007, 27:1511-1518.
18. Lee S.R., Kiyoshi T., Lee S.R., Lo E.H. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. JNeurosci 2004, 24:671-678.
19. Nogawa S., Zhang F., Ross M.E., Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. JNeurosci 1997, 17:2746-2755.
20. Nakayama M., Uchimura K., Zhu R.L., Nagayama T., Rose M.E., Stetler R.A., et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998, 95:10954-10959.
21. Mohammad Iqbal H.B., Youn J.K. Mechanisms and prospects of ischemic tolerance induced by cerebral preconditioning. Int Neurourol J 2010, 14:203-212.
22. Irving E.A., Bamford M. Role of mitogen-and stress-activated kinases is ischemic injury. JCereb Blood Flow Metab 2002, 22:631-647.
23. Qiao H.M., Zhang X.J., Zhu C.H., Dong L.P., Wang L.N., Zhang X.L., et al. Luteolin downregulates TLR4, TLR5, NF-κB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia. Brain Res 2012, 1448:71-81.
24. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344.
25. Chen J., Li C., Pei D.S., Han D., Liu X.M., Jiang H.X., et al. GluR6-containing KA receptor mediates the activation of p38 MAP Kinase in rat hippocampal CA1 region during brain ischemia injury. Hippocampus 2009, 19:79-89.
26. Li D.Y., Tao L., Liu H., Christopher T.A., Lopez B.L., Ma X.L. Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitricoxide after myocardial ischemia and reperfusion. Apoptosis 2006, 11:923-930.
27. Ostrakhovitch E.A., Cherian M.G. Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis. JCell Biochem 2005, 95:1120-1134.
28. Stoica B.A., Movsesyan V.A., Knoblach S.M., Faden A.I. Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins. Mol Cell Neurosci 2005, 29:355-371.
29. Borsello T., Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007, 13:1875-1886.
30. Cheyuo C., Jacob A., Wu R., Zhou M., Qi L., Dong W., et al. Recombinant human MFG-E8 attenuates cerebral ischemic injury: its role in anti-inflammation and anti-apoptosis. Neuropharmacology 2012, 62:890-900.
31. Maddahi A., Edvinsson L. Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. JNeuroinflammation 2010, 26:7-14.
32. Xie Z., Smith C.J., Van Eldik L.J. Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia 2004, 45:170-179.
33. Han J.Y., Fan J.Y., Horie Y., Miura S., Cui D.H., Ishii H., et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008, 117:280-295.
34. Du W., Wei Y.H., Zhao G. Simultaneous determination of four tanshinones in rat plasma by high performance liquid chromatography and its application to pharmacokinetic studies. JChin Pharm 2008, 43:786-790.
35. Chen X., Zhou Z.W., Xue C.C., Li X.X., Zhou S.F. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 2007, 37:635-678.
36. Vlieghe P., Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev 2012 Mar 20, [Epub ahead of print]. 10.1002/med.21252.
37. Gabathuler R. Approaches to transport therapeutic drugs across the blood brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57.
38. Parikh T., Bommana M.M., Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur J Pharm Biopharm 2010, 74:442-450.
39. Karakoti A.S., Das S., Thevuthasan S., Seal S. PEGylated inorganic nanoparticles. Angew Chem Int Ed 2011, 50:1980-1994.
40. Cimini A., D'Angelo B., Das S., Gentile R., Benedetti E., Singh V., et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater 2012, 8:2056-2067.
41. Liu X., An C.Y., Jin P., Liu X.S., Wang L.H. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemi. Biomaterials 2013, 34:817-830.
42. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996, 93:14164-14169.
43. Lu W., Wan J., She Z., Jiang X.G. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated NPs. JControl Release 2007, 118:38-53.
44. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
45. Breckwoldt M.O., Chen J.W., Stangenberg L., Aikawa E., Rodriguez E., Qiu S., et al. Tracking the inflammatory response in stroke invivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci USA 2008, 105:18584-18589.
46. Lu W., Zhang Y., Tan Y.Z., Hu K.L., Jiang X.G., Fu S.K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. JControl Release 2005, 107:428-448.
47. Liu J.P., Zhu J.B., Du Z.Y., Qin B. Preparation and pharmacokinetic evaluation of tashinone IIA solid lipid nanoparticles. Drug Dev Ind Pharm 2005, 31:551-556.
48. Xiao R.Z., Zeng Z.W., Zhou G.L., Wang J.J., Li F.Z., Wang A.M. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomed 2010, 26:1057-1065.
49. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocyte system. JPharm Sci 1995, 84:493-498.
50. Pfefferkorn T., Rosenberg G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003, 34:2025-2030.
51. Calvo P., Gouritin B., Chacun H., Desmaële D., D'Angelo J., Noel J.P., et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001, 18:1157-1166.
52. Chao X.D., Zhou J., Chen T., Liu W.B., Dong W.P., Qu Y., et al. Neuroprotective effect of osthole against acute ischemic stroke on middle cerebral ischemia occlusion in rats. Brain Res 2010, 1363:206-211.
53. Gao F., Yue T.L., Shi D.W., Christopher T.A., Lopez B.L., Ohlstein E.H., et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 2002, 53:414-422.
54. 4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res 2010, 1323:174-183.
55. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
56. Ferrer I., Friguls B., Dalfo E., Planas A.M. Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia. Acta Neuropathol 2003, 105:425-437.
57. Namura S., Lihara K., Takami S., Nagata I., Kikuchi H., Matsushita K., et al. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci USA 2001, 98:11569-11574.
58. Yang H., Zhang J., Andreasson K., Chen C. COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Mol Cell Neurosci 2008, 37:682-695.